Baader Bank Aktiengesellschaft Lowers Position in Gilead Sciences, Inc. $GILD

Baader Bank Aktiengesellschaft cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 35.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 6,993 shares of the biopharmaceutical company’s stock after selling 3,790 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Gilead Sciences were worth $844,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth $28,000. Financial Consulate Inc. grew its holdings in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the period. North Star Investment Management Corp. grew its holdings in shares of Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the period. BOCHK Asset Management Ltd purchased a new position in shares of Gilead Sciences during the 4th quarter worth $31,000. Finally, MTM Investment Management LLC grew its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD opened at $132.06 on Friday. The stock’s 50-day moving average price is $138.14 and its 200 day moving average price is $133.25. Gilead Sciences, Inc. has a 12-month low of $97.86 and a 12-month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a market cap of $163.96 billion, a price-to-earnings ratio of 17.99 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the company earned $1.81 EPS. Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wolfe Research increased their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft increased their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Morgan Stanley decreased their target price on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Barclays began coverage on Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price on the stock. Finally, Jefferies Financial Group began coverage on Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price on the stock. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $157.04.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares of the company’s stock, valued at $24,835,883.36. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the insider directly owned 128,779 shares in the company, valued at $18,152,687.84. This represents a 2.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,000 shares of company stock valued at $9,238,250 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.